Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082501 | 0.82 | CYP2D6 (0.42) | CYP2D6CYP2C19MEN1KMT2AECE1 | |
| SCHEMBL10308211 | 0.80 | MTNR1A (0.40) | CYP2D6CYP2C19MEN1KMT2AALDH1A1 | |
| SCHEMBL11676865 | 0.79 | CYP2D6 (0.54) | CYP2D6CYP2C19TP53MEN1KMT2A | |
| SCHEMBL30572006 | 0.79 | CYP2D6 (0.54) | CYP2D6CYP2C19TP53MEN1KMT2A | |
| SCHEMBL3115481 | 0.79 | — | — | |
| SCHEMBL593908 | 0.79 | — | — | |
| SCHEMBL1982391 | 0.79 | — | — | |
| SCHEMBL6728230 | 0.77 | CYP2D6 (0.64) | CYP2D6CYP2C19TP53MEN1KMT2A | |
| SCHEMBL28716386 | 0.77 | CYP2D6 (0.64) | CYP2D6CYP2C19TP53MEN1KMT2A | |
| SCHEMBL28386448 | 0.76 | CYP2D6 (0.45) | CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609888-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2020-02-19 | — | — | EP | claimed |
| WO-2018170182-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2018-09-20 | — | — | WO | claimed |
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | CYP2D6 1529/4885CYP2C19 1340/4885TP53 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.